olanzapine and Stomach-Neoplasms

Cisplatin is commonly used for esophageal and gastric cancer, but has a high emetic risk. Although the control of vomiting is favorable, nausea is still poorly controlled in patients receiving cisplatin-based regimens. The present study was designed to determine the risks for cisplatin-induced nausea. The effect of olanzapine, an antipsychotic drug, as an antiemetic for patients with risk of poor control of nausea was subsequently examined.. The prevalence of antiemetic medication and the control of nausea and vomiting were retrospectively examined in patients with esophageal or gastric cancer receiving the first cycle of cisplatin-based chemotherapy. Risks for nausea were analyzed by multivariate logistic regression analysis, in which threshold for age and cisplatin dose wer assessed by receiver operating characteristic curve analysis.. A total of 186 patients received cisplatin-based regimens during January 2011 and December 2016. Guideline-consistent antiemetic medication was administered to all patients. Although the rate of no vomiting was high (93%), the rate of non-significant (grade 2 or more) nausea was insufficient (64%) during the overall period. Risk analysis showed that cisplatin dose of 50 mg/m. Being female and cisplatin doses at 50 mg/m

Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepines; Cisplatin; Dose-Response Relationship, Drug; Esophageal Neoplasms; Female; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Nausea; Olanzapine; Retrospective Studies; Risk Factors; Sex Factors; Stomach Neoplasms

Here we present a case of successful treatment employing a mixed approach including pharmacological and psychosomatic treatments for a 72-year-old woman who experienced severe nausea and vomiting in reaction to postoperative stress from gastric cancer surgery. This case demonstrates that appropriate provision of psychosomatic treatments, including a psychotherapeutic session and autogenic training, enhances the efficacy of pharmacotherapy.

Topics: Aged; Amoxapine; Anti-Anxiety Agents; Antidepressive Agents; Antiemetics; Benzodiazepines; Bromazepam; Clomipramine; Combined Modality Therapy; Female; Humans; Mianserin; Mirtazapine; Nausea; Olanzapine; Physical Therapy Modalities; Postoperative Complications; Psychotherapy; Stomach Neoplasms; Stress, Psychological; Vomiting

In May, 2009, a man in his 30s presented to the department of outpatient palliative care of this hospital. His chief complaints were of severe nausea and abdominal fullness associated with cancerous peritonitis following surgery for gastric cancer. Abdominal fullness was reduced after the initiation of a continued subcutaneous administration of octreotide acetate, but combination therapy with metoclopramide and domperidone did not relieve nausea. The administration of olanzapine orally disintegrating tables (OLZ-ODT) at a dose of 10 mg twice daily was associated with the tendency to reduce nausea. As the symptoms were relieved, palliative care at his home was initiated. The patient's self-discontinuation of OLZ-ODT because the nausea was relieved resulted in its aggravation, but it was relieved again when the administration was resumed. Subsequently, home care was possible for approximately two and half a months without aggravation. Maintaining nausea control well leads to higher-quality care. OLZ-ODT appears to not only be effective for relieving nausea associated with cancerous peritonitis, but is also important for disseminating palliative care at home.

Topics: Administration, Oral; Adult; Benzodiazepines; Fatal Outcome; Home Care Services; Humans; Male; Olanzapine; Palliative Care; Peritonitis; Stomach Neoplasms; Tomography, X-Ray Computed

This paper reports the case of a 64-year-old man who was receiving parenteral nutrition after repeated operations due to stomach cancer. Olanzapine (orally disintegrating tablets) in combination with alprazolam was used successfully to relieve this terminally ill patient's anxiety and tension improving his relationship with his physicians and his daily life.

Topics: Administration, Sublingual; Alprazolam; Anti-Anxiety Agents; Anxiety Disorders; Benzodiazepines; Humans; Male; Middle Aged; Olanzapine; Parenteral Nutrition; Professional-Patient Relations; Quality of Life; Stomach Neoplasms; Terminally Ill